News from BusinessWire. Look at the caliber of the 2 new directors.
( BW)(PARACELSIAN)(PRLN) Paracelsian adds two new board members
ITHACA, N.Y.--(BUSINESS WIRE)--July 22, 1996--Paracelsian Inc. (NASDAQ:PRLN) today announced that William J. Warwick, who has served the company as a special consultant to the Board for China operations and Jack O'Reilly, president of Vectorpharma International Corp., have been elected directors of the company, expanding the board to nine members.
The announcement was made by Keith A. Rhodes, president and chief executive officer of the company.
"We are extremely pleased to welcome two men of the caliber of Mr. Warwick and Mr. O'Reilly," said Rhodes, noting that "both men bring tremendous experience and expertise to Paracelsian as we move forward."
Warwick, who is a senior vice president of AT&T, is chairman and chief executive officer of AT&T China. He is responsible for the AT&T business operations in China and for overall corporate planning for AT&T businesses in China, Hong Kong and Taiwan. He has been with AT&T for more than 35 years, serving in a variety of positions throughout the organization. These included work in government and labor relations; manufacturing; and work with AT&T information systems for both business and residence products. In 1984 he became a group vice president for Consumer Products; in 1986, group vice president, engineering, manufacturing and production planning; and in 1987, president of AT&T Microelectronics. He holds an MBA from Northwestern University and a Bachelor of Science degree in Business Administration from the University of North Carolina.
O'Reilly, who joined Vectorpharma International Corp. in 1993, has negotiated development agreements for drug molecules with major companies, as well as had extensive experience in the establishment of relationships with Japanese and Korean companies. Prior to joining Vectorpharma International Corp., he was a consultant, working with companies that included Spectra Biomedical Inc., Abaxis Inc., and Pharmetrix. From 1974 through 1992, he held a variety of positions at Syntex Corp., including senior director of corporate and business development; group finance director of pharmaceuticals and animal health; regional finance director, Americas & Pacific; finance and administration director, France; finance director, Switzerland and regional planning manager, Europe. He also worked at McKinsey & Co., Inc., as a consultant, and began his career at Bank of London & South America, Ltd. He holds an MBA from Stanford Graduate School of Business and a Bachelor of Arts in Modern History from Oxford University.
Paracelsian is a biotechnology company engaged in the discovery of pharmaceuticals from herbal sources and the development and marketing of tests for improved cancer diagnosis and environmental carcinogens, utilizing the proprietary signal transduction technology of the company. Currently the company has compassionate use trials underway for its compound PN 27, 1, which has been found to have safe and effective activity against prostate and breast cancers and non-Hodgkin's lymphomas, as well as initial clinical trials at the Bastyr University in Seattle for its PN 355 compound, which has been found to have specific activity against HIV.
--30--amp/ny*
CONTACT: Arthur A. Koch
Paracelsian Inc.
607/257-4224
or
Bev Jedynak
312/943-1100 |
